HOUSTON, TEX. -- ONCOLIX, INC., announced today that it has completed a Series A round of financing, led by PoC Capital, LLC and Integrium Clinical Research, LLC. Also participating in the finance round was the Texas Emerging Technology Fund and certain healthcare-focused investors, representing gross proceeds to ONCOLIX of approximately $4.2 million. ONCOLIX plans to use the net proceeds from the offering to fund activities relating to its drug candidate, ProlantaTM, for a Phase I dose-escalation clinical trial for the treatment of ovarian cancer.
Technology news on Global TechWire, reporting the business of life
sciences and innovation. Published by Innovative Public Relations, Inc.,
a Research Triangle, North Carolina-based publicity and branding
consultancy. Learn more @ www.innovativepublicrelations.com.
About ONCOLIX
ONCOLIX is a privately-held, clinical-stage biotechnology company focused on the development of ProlantaTM to treat cancer. The FDA has cleared the Company's Investigational New Drug Application (IND) for a Phase I clinical trial for the treatment of ovarian cancer. This trial is expected to commence in 2015.
About ProlantaTM
ProlantaTM is a therapeutic protein with a novel mechanism of action called autophagy, or autophagocytosis. ProlantaTM targets human prolactin, which is implicated in proliferation of cancer cells, and has the potential to treat ovarian, breast, prostate and other solid tumor cancers. Prolanta's mechanism of action was described in a publication (Cell Reports) in April, 2014, written by scientists at The University of Texas MD Anderson Cancer Center. "Prolactin is a potent growth factor for many types of cancers, including ovarian cancer," said senior author Anil Sood, M.D., professor of Gynecologic Oncology. "When we block prolactin signaling, it sets off a chain of downstream events that result in cell death by autophagy."
More information can be found on the Company's web site at www.oncolixbio.com.
Contact:
Oncolix, Inc. Michael Redman, CEO mredman@oncolixbio.com 281-402-3167
About Integrium, LLC
Integrium Clinical Research specializes in the strategy, study design, and execution of Phase I-IV clinical trials, with an expertise in Proof of Concept trials. The firm has strong clinical trial experience in a range of therapeutic indications including cardiovascular, metabolic, renal, inflammatory, dermatology, regenerative, orphan, and wound healing drug development. It has a strong reputation for delivering high-quality management of global clinical development programs and service to its clients. Combining the Integrium Clinical Excellence (ICE) study start-up and management methodology, and therapeutic expertise leads sponsors to more confident, better-informed drug and device development decisions. For more information please visit www.integrium.com.
